Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

Next Previous
Trial Profile

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Romidepsin (Primary) ; Belinostat; Gemcitabine; Pralatrexate
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Lymphoproliferative disorders; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms PTCL

Most Recent Events

  • 04 Jul 2025 Planned End Date changed from 2 Jun 2028 to 2 Jun 2030.
  • 04 Jul 2025 Planned primary completion date changed from 2 Jun 2026 to 2 Jun 2028.
  • 09 Jul 2024 Planned primary completion date changed from 2 Dec 2026 to 2 Jun 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top